CVRx, Inc. (CVRX) Earnings Call Transcripts
CVRx, Inc.'s Latest Earnings Call - June 10, 2026
In the second quarter of fiscal year 2026, CVRx, Inc. reported a revenue of $34 million, reflecting a 20% growth compared to the same quarter last year, exceeding the company's guidance of $31 million to $33 million. The company maintained its full-year revenue guidance of $63 million to $67 million, signaling confidence in its growth trajectory despite ongoing challenges in the heart failure device market. Management emphasized the positive impact of recent reimbursement developments, particularly with Humana, which is expected to enhance patient access and drive adoption of their Barostim therapy.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $34M (beat) |
| Full-Year Revenue Guidance | $63M-$67M (inline) |
| Q1 Revenue Growth | 20% (beat) |
| Market Opportunity | $30B (positive) |
| Sales Team Transition | 70% (positive) |
| Medicare Advantage Approval Rate | 49% (positive) |
Guidance from management
Management maintained its full-year revenue guidance of $63 million to $67 million, indicating confidence in achieving growth despite market challenges.
What analysts pressed on
Analysts expressed concerns about the slow adoption of heart failure devices and the potential need for partnerships to accelerate growth. Questions were raised regarding the sustainability of growth and the effectiveness of the current sales strategy in a conservative market.
Main topics on the call
- Revenue Growth Acceleration — CVRx reported a revenue of $34 million for Q2 2026, representing a 20% increase year-over-year, and exceeding guidance. Management stated, "Q1 results were closer to 20% growth across the worldwide business, even greater...
- CFO Transition — The company announced the planned transition of CFO Jared Oasheim, who will remain for 9-10 months to ensure a smooth handover. Oasheim stated, "I want to make sure that this company continues on in a very strong way and...
- Market Opportunity Expansion — Management highlighted a potential market expansion with the upcoming benefit trial, which could triple the addressable market from $10 billion to $30 billion. Oasheim noted, "By enrolling 2,500 patients, by expanding th...
- Reimbursement Developments — CVRx received a significant boost with Humana's recent coverage policy for Barostim therapy, which management described as a "welcome surprise". This policy allows CVRx to reference it in prior authorizations, enhancing ...
Read the full CVRx, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About CVRx, Inc.
CVRx, Inc. (CVRX) is a publicly listed company in the Health Care Equipment and Supplies industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 26 calls on record spanning February 15, 2022 to August 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 26 CVRx, Inc. earnings call transcripts on record, spanning February 15, 2022 to August 6, 2026. Based on this history, CVRx, Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- CVRX
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Calls on record
- 26
- First call
- February 15, 2022
- Most recent
- August 6, 2026
- Reporting cadence
- quarterly